HC Wainwright Reaffirms Buy Rating for MediWound (NASDAQ:MDWD)

MediWound (NASDAQ:MDWD)‘s stock had its “buy” rating restated by analysts at HC Wainwright in a research note issued on Thursday,Benzinga reports. They currently have a $25.00 price objective on the biopharmaceutical company’s stock. HC Wainwright’s target price would suggest a potential upside of 53.66% from the company’s current price. HC Wainwright also issued estimates for MediWound’s FY2029 earnings at $2.45 EPS.

Separately, Craig Hallum began coverage on shares of MediWound in a research report on Friday, February 28th. They issued a “buy” rating and a $39.00 target price for the company.

MediWound Stock Down 4.6 %

Shares of MDWD stock opened at $16.27 on Thursday. The firm has a fifty day moving average of $18.17 and a 200-day moving average of $17.58. MediWound has a 12-month low of $12.78 and a 12-month high of $24.00. The company has a market capitalization of $175.49 million, a price-to-earnings ratio of -5.61 and a beta of 0.82.

MediWound (NASDAQ:MDWD) last issued its quarterly earnings data on Wednesday, March 19th. The biopharmaceutical company reported ($0.36) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.59) by $0.23. The company had revenue of $5.84 million during the quarter, compared to the consensus estimate of $5.79 million. MediWound had a negative net margin of 142.29% and a negative return on equity of 82.17%. During the same quarter in the prior year, the firm earned ($0.19) earnings per share. On average, equities analysts expect that MediWound will post -2.66 EPS for the current year.

Institutional Trading of MediWound

A number of hedge funds have recently modified their holdings of the stock. Investor AB acquired a new stake in shares of MediWound during the 3rd quarter worth about $15,750,000. Yelin Lapidot Holdings Management Ltd. lifted its stake in shares of MediWound by 13.4% during the 4th quarter. Yelin Lapidot Holdings Management Ltd. now owns 851,361 shares of the biopharmaceutical company’s stock worth $15,154,000 after buying an additional 100,618 shares during the last quarter. Essex Investment Management Co. LLC lifted its stake in shares of MediWound by 30.7% during the 4th quarter. Essex Investment Management Co. LLC now owns 148,949 shares of the biopharmaceutical company’s stock worth $2,651,000 after buying an additional 35,012 shares during the last quarter. Northern Trust Corp lifted its stake in shares of MediWound by 94.6% during the 4th quarter. Northern Trust Corp now owns 144,768 shares of the biopharmaceutical company’s stock worth $2,577,000 after buying an additional 70,367 shares during the last quarter. Finally, Sargent Investment Group LLC lifted its stake in shares of MediWound by 3.4% during the 4th quarter. Sargent Investment Group LLC now owns 121,190 shares of the biopharmaceutical company’s stock worth $2,217,000 after buying an additional 3,998 shares during the last quarter. Institutional investors and hedge funds own 46.83% of the company’s stock.

MediWound Company Profile

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.